- “You have to make a distinction between the science and the technological applications,” says Francis Fukuyama, a member of the President’s Council on Bioethics and director of the Human Biotechnology Governance Project. “It’s probably true that in terms of the basic science, it’s pretty hard to stop that. It’s not one guy in a laboratory somewhere. But not everything that is scientifically possible will actually be technologically implemented and used on a large scale. In the case of human cloning, there’s an abstract possibility that people will want to do that, but the number of people who are going to want to take the risk is going to be awfully small.” Taboos will play an important role, Fukuyama says. “We could really speed up the whole process of drug improvement if we did not have all the rules on human experimentation. If companies were allowed to use clinical trials in Third World countries, paying a lot of poor people to take risks that you wouldn’t take in a developed country, we could speed up technology quickly.” But because of the Holocaust, Fukuyama thinks, the school of hard knocks will slow down a lot of attempts. “People may in the abstract say that they’re willing to take that risk. But the moment you have a deformed baby born as a result of someone trying to do some genetic modification, I think there will be a really big backlash against it.” quoted in “Inventing Our Evolution” published Monday, May 16, 2005 in the Washington Post.
Earlier versions are here and here.